Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHB-171 in Chronic Hepatitis B
NCT07617194Phase 1Not yet recruiting
- Sponsor
- AusperBio
- Start
- Jul 2026
- Primary completion
- Oct 2027
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of AHB-171 in Chronic Hepatitis B (CHB) (4 arms), sponsored by AusperBio. Primary endpoints: Incidence of Adverse Events up to 72 weeks, Maximum observed plasma concentration of AHB-171 up to 72 weeks and 5 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
AHB-171
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07617194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07617194.